MiNK Therapeutics (INKT) Scheduled to Post Quarterly Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect MiNK Therapeutics to post earnings of ($0.08) per share for the quarter.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts expect MiNK Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiNK Therapeutics Price Performance

INKT stock opened at $0.75 on Tuesday. MiNK Therapeutics has a twelve month low of $0.57 and a twelve month high of $1.90. The business has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $0.86. The company has a market cap of $29.66 million, a price-to-earnings ratio of -1.53 and a beta of 0.05.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of MiNK Therapeutics in a research note on Wednesday, October 9th.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.